Updates on radiotherapy-immunotherapy combinations: Proceedings of 6 th annual ImmunoRad conference.
Fabiana GregucciSheila SpadaMary Helen Barcellos-HoffNina BhardwajCharleen Chan Wah HakAlba FiorentinoChandan GuhaMonica L GuzmanKevin J HarringtonFernanda G HerreraJamie HoneychurchTheodore S HongLorea IturriElisabeth JaffeeSana D KaramSimon R V KnottConstantinos KoumenisDavid C LydenAriel E MarciscanoAlan A MelcherMichele MondiniAnna MondinoZachary S MorrisSean P PitrodaSergio A QuezadaLaura SantambrogioStephen L ShiaoJohn StaggIrma TelarovicRobert TimmermanMarie-Catherine VozeninRalph R WeichselbaumJames WelshAnna C WilkinsChris XuRoberta ZappasodiWeiping ZouAlexandre BobardSandra DemariaLorenzo GalluzziEric DeutschSylvia C FormentiPublished in: Oncoimmunology (2023)
Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.